Results 151 to 160 of about 3,573 (200)

CGRP-targeted therapeutics for migraine: a clinical trial landscape analysis. [PDF]

J Transl Med
Li J, Huang L, Guo X, Wu R, Liu Z, Xie S, Wang G.   +6 more
europepmc   +1 more source

Health care resource utilization and direct costs incurred over 12 months by patients with migraine initiating self-injectable calcitonin gene-related peptide monoclonal antibodies: A US real-world study. [PDF]

J Manag Care Spec Pharm
Varnado OJ, Brady B, Zagar A, Robles Y, Ó Céilleachair A, Hoyt M.   +5 more
europepmc   +1 more source

Effect of erenumab versus other migraine preventive medications on cardiovascular and cerebrovascular outcomes: A United States claims database-based observational cohort study. [PDF]

Headache
Dodick DW, Tepper SJ, Ailani J, Khodavirdi AC, Pannacciulli N, Fu A, Kent ST, Gill K, Urman R, Oh SS.   +9 more
europepmc   +1 more source

Plasma SuPAR and therapeutic response to erenumab in migraine: a REFORM study. [PDF]

J Headache Pain
Karlsson WK, Christensen RH, Al-Khazali HM, Kallemose T, Jawad BN, Andersen O, Ashina M, Ashina H.   +7 more
europepmc   +1 more source

Correction: Increased infection risk in patients on preventive CGRP-targeting therapies- a meta-analysis and clinical effect assessment. [PDF]

J Headache Pain
Straburzyński M, Kopyt D, Marschollek K, Błaszczyk B, Kuca-Warnawin E, Kurowska W, Misiak B, Peng KP, Waliszewska-Prosół M, May A.   +9 more
europepmc   +1 more source

Erenumab for migraine.

Australian prescriber
openaire   +1 more source

Some of the next articles are maybe not open access.

Related searches:

Erenumab

Reactions Weekly, 2021
Do, Thien Phu, Younis, Samaira, Ashina, Messoud   +2 more
  +8 more sources

Erenumab for episodic migraine

Pain Management, 2022
In this review, the authors provide an overview of erenumab, a monoclonal antibody used for the preventative treatment of episodic migraine by targeting the CGRP pathway. Randomized controlled trials have shown that erenumab is associated with a statistically significant decrease in monthly migraine days in patients with episodic migraine at monthly ...
Abhigyan Datta, Sahil Gupta, Shashi Maryala, Vikram Aggarwal, Pooja Chopra, Sameer Jain   +5 more
openaire   +2 more sources

Erenumab

pharma-kritik, 2018
Ein neues Medikament, das zur Prävention bei Migräne eingesetzt werden kann. Erenumab, das einmal monatlich subkutan injiziert wird, hat sich in mehreren Studien als wirksamer als Placebo gezeigt.
openaire   +1 more source

Erenumab

Reactions Weekly, 2022
  +6 more sources